360 related articles for article (PubMed ID: 21633782)
1. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization.
Shalhoub V; Ward SC; Sun B; Stevens J; Renshaw L; Hawkins N; Richards WG
Calcif Tissue Int; 2011 Aug; 89(2):140-50. PubMed ID: 21633782
[TBL] [Abstract][Full Text] [Related]
2. Soluble Klotho causes hypomineralization in Klotho-deficient mice.
Minamizaki T; Konishi Y; Sakurai K; Yoshioka H; Aubin JE; Kozai K; Yoshiko Y
J Endocrinol; 2018 Jun; 237(3):285-300. PubMed ID: 29632215
[TBL] [Abstract][Full Text] [Related]
3. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease.
Carrillo-López N; Panizo S; Alonso-Montes C; Román-García P; Rodríguez I; Martínez-Salgado C; Dusso AS; Naves M; Cannata-Andía JB
Kidney Int; 2016 Jul; 90(1):77-89. PubMed ID: 27165819
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency.
Jimbo R; Kawakami-Mori F; Mu S; Hirohama D; Majtan B; Shimizu Y; Yatomi Y; Fukumoto S; Fujita T; Shimosawa T
Kidney Int; 2014 May; 85(5):1103-11. PubMed ID: 24088960
[TBL] [Abstract][Full Text] [Related]
5. FGF23 Regulates Bone Mineralization in a 1,25(OH)2 D3 and Klotho-Independent Manner.
Murali SK; Roschger P; Zeitz U; Klaushofer K; Andrukhova O; Erben RG
J Bone Miner Res; 2016 Jan; 31(1):129-42. PubMed ID: 26235988
[TBL] [Abstract][Full Text] [Related]
6. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro.
Xiao L; Esliger A; Hurley MM
J Bone Miner Res; 2013 Jan; 28(1):35-45. PubMed ID: 22836867
[TBL] [Abstract][Full Text] [Related]
7. The suppressive effect of soluble Klotho on fibroblastic growth factor 23 synthesis in UMR-106 osteoblast-like cells.
Ma L; Gao M; Wu L; Zhao X; Mao H; Xing C
Cell Biol Int; 2018 Sep; 42(9):1270-1274. PubMed ID: 29851201
[TBL] [Abstract][Full Text] [Related]
8. Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-α and GPR30 mediated p38 signalling pathway on MC3T3-E1 cells.
Wu QC; Tang XY; Dai ZQ; Dai Y; Xiao HH; Yao XS
Phytomedicine; 2020 Mar; 68():153146. PubMed ID: 32028183
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic Actions of FGF23.
Erben RG
Toxicol Pathol; 2017 Oct; 45(7):904-910. PubMed ID: 29096595
[TBL] [Abstract][Full Text] [Related]
10. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.
Xiao L; Naganawa T; Lorenzo J; Carpenter TO; Coffin JD; Hurley MM
J Biol Chem; 2010 Jan; 285(4):2834-46. PubMed ID: 19933269
[TBL] [Abstract][Full Text] [Related]
11. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].
Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 23 inhibits osteoblastic gene expression and induces osteoprotegerin in vascular smooth muscle cells.
Nakahara T; Kawai-Kowase K; Matsui H; Sunaga H; Utsugi T; Iso T; Arai M; Tomono S; Kurabayashi M
Atherosclerosis; 2016 Oct; 253():102-110. PubMed ID: 27599364
[TBL] [Abstract][Full Text] [Related]
13. Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures.
Luppen CA; Smith E; Spevak L; Boskey AL; Frenkel B
J Bone Miner Res; 2003 Jul; 18(7):1186-97. PubMed ID: 12854828
[TBL] [Abstract][Full Text] [Related]
14. Klotho/FGF23 Axis in CKD.
Tsuchiya K; Nagano N; Nitta K
Contrib Nephrol; 2015; 185():56-65. PubMed ID: 26023015
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients.
Krajisnik T; Olauson H; Mirza MA; Hellman P; Akerström G; Westin G; Larsson TE; Björklund P
Kidney Int; 2010 Nov; 78(10):1024-32. PubMed ID: 20686451
[TBL] [Abstract][Full Text] [Related]
16. The parathyroid is a target organ for FGF23 in rats.
Ben-Dov IZ; Galitzer H; Lavi-Moshayoff V; Goetz R; Kuro-o M; Mohammadi M; Sirkis R; Naveh-Many T; Silver J
J Clin Invest; 2007 Dec; 117(12):4003-8. PubMed ID: 17992255
[TBL] [Abstract][Full Text] [Related]
17. Klotho converts canonical FGF receptor into a specific receptor for FGF23.
Urakawa I; Yamazaki Y; Shimada T; Iijima K; Hasegawa H; Okawa K; Fujita T; Fukumoto S; Yamashita T
Nature; 2006 Dec; 444(7120):770-4. PubMed ID: 17086194
[TBL] [Abstract][Full Text] [Related]
18. FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice.
Du E; Xiao L; Hurley MM
J Cell Physiol; 2017 Mar; 232(3):610-616. PubMed ID: 27306296
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.
Bacchetta J; Sea JL; Chun RF; Lisse TS; Wesseling-Perry K; Gales B; Adams JS; Salusky IB; Hewison M
J Bone Miner Res; 2013 Jan; 28(1):46-55. PubMed ID: 22886720
[TBL] [Abstract][Full Text] [Related]
20. FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation.
Kyono A; Avishai N; Ouyang Z; Landreth GE; Murakami S
J Bone Miner Metab; 2012 Jan; 30(1):19-30. PubMed ID: 21678127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
